newsfilter
← Latest News
GlobeNewswire·

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered into an